Laurus Labs Limited (NSE: LAURUSLABS) has unveiled robust financial results for the first half of FY 2027, showcasing a significant revenue of ₹4,233 crore, marking a 31% year-on-year growth. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹1,406 crore, reflecting a strong operational performance.

Strong Revenue and Margin Expansion

The company’s robust performance is driven by sustained growth in its Contract Development and Manufacturing Organization (CDMO) segment, which has seen commercial supplies and a steady momentum in its Affordable Medicines division. The gross margins expanded by over 3.3% points to 62.9%, supported by a healthy business segment mix.

Strategic Investments

Laurus Labs Limited has also announced strategic investments in two technology platforms to bolster its Integrated CDMO offering. The company has entered into a definitive agreement to acquire a 60% stake in Galenvs, a specialized firm in Oligonucleotide and Precision Magnetic Nanoparticles for purification. This acquisition aims to expand Laurus’s position in the fast-growing Oligo market, which is projected to reach $11 billion by 2030, with a CAGR of 22-24%.

Additionally, Laurus Labs plans to acquire a 52% stake in SI &C Resins, a company with expertise in peptide/polymer chemistry. This acquisition will enhance the company’s manufacturing competitiveness and reliability, particularly in the rapidly expanding GLP-1 and non-GLP-1 peptide drugs market.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Laurus Labs Limited

Laurus Labs Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Laurus gains 34.7% over three months and trades near its 52-week highs. The PEG stands at 25.45 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock trades at 98% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 34.7% in three months. Yet revenue grows at only 3.8% and the PEG stands at 25.45. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Laurus Labs Limited.

Max India Limited (MAXIND) has announced the completion of 200 homes at its Noida senior living community, Antara Noida, marking a significant milestone. The handover of these homes within less than two months of beginning the possession process underscores the company’s commitment to its integrated approach to senior living.

Integrated Senior Living Approach

Antara Senior Care, the senior-care business of Max India Limited, has completed the handover of 200 apartments at Antara Noida, its senior-living residential community in Sector 150, Noida. This achievement highlights the company’s dedication to providing a comprehensive ecosystem that combines purpose-designed residences with wellness, care, and lifestyle services.

Commitment to Senior Independence

Rajit Mehta, Managing Director & CEO of Antara Senior Living Limited and Max India, emphasized the company’s belief in senior living as more than just a place to live. ‘We believe that senior living should be about having the freedom to live life on one’s own terms, with the confidence that care and support are always within reach,’ said Mehta. The completion of 200 homes signifies a crucial step in this journey, reinforcing the company’s mission to build communities where seniors feel supported, inspired, and empowered.

Antara Noida, located in Sector 150, Noida, is a senior-living community with a total of 340 units designed to create an ecosystem where care evolves with the changing needs of seniors. The community aims to support seniors’ independence, wellbeing, and social connection through a blend of thoughtfully curated life care and lifestyle offerings.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max India Limited

Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 13.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.

Senores Pharmaceuticals Limited (SENORES) announced its unaudited financial results for the quarter and half year ended 30th September 2026, showcasing robust financial and operational performance. The company reported a 25% year-on-year increase in revenue for Q2 FY27 and a 38% rise in EBITDA, marking consistent strong growth across its businesses.

Segmental Highlights

The company’s revenue for Q2 and H1 FY27 grew by 25% and 30% respectively on a year-on-year basis. Notably, the Regulated Markets segment saw a 34% increase in revenue, while the Emerging Markets segment grew by 21% in Q2 and 25% in H1 FY27. The company’s portfolio in Regulated Markets nearly doubled, expanding from 34 ANDAs as of September 2025 to 64 ANDAs as of September 2026, with 23 commercialized products.

Operational Excellence

Despite initial set-up and operating costs associated with Zoraya and Amerisyn, EBITDA for Q2 and H1 FY27 grew by 38% and 58% respectively, with margin expansion of approximately 290 bps and 530 bps on a year-on-year basis. The company’s cash from operations stood at ₹38 crores in H1 FY27, reflecting a consistent improvement in cash flow generation.

Forward-Looking Outlook

Senores Pharmaceuticals Limited remains optimistic about its future growth trajectory, on track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27. The company’s robust product pipeline, expanded manufacturing capabilities, and strong commercial launch visibility underpin its positive outlook for the year and beyond.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Senores holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.33 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 159.1% and profits at 139.2% CAGR. Both numbers are exceptional. The stock holds at 69% of its 52-week range with RSI at 44. In other words, neither side has a clear edge right now. Both the business and the stock move in the right direction. Revenue grows at 159.1%, profits at 139.2%, and the PEG sits at 0.33 — below its growth rate. That combination is rare. Check Fundamentals of Senores Pharmaceuticals Limited.